AORT (Artivion) סך נכסים נקיים

The Artivion, Inc. (AORT) price chart demonstrates the impact of ESG initiatives aimed at reducing manufacturing waste and energy consumption. The high cost of unique cardiac implants and physicians' price insensitivity maintain margins at 0.44. The business relies on the creation of bioprosthetic valves: following FDA approval, production costs decline, while global demand ensures stable revenue through patent scalability.

This indicator reflects the total net asset value of Artivion, Inc. (AORT), calculated as the difference between all company assets and liabilities. By analyzing the company's balance sheet capitalization on the GURU.Markets platform, an investor assesses the business's internal reserves, which for this cardio-implant manufacturer are supported by stable demand for life-critical products and predictable cash flows.